Chlamydial Respiratory Infection during Allergen Sensitization Drives Neutrophilic Allergic Airways Disease

Jay C. Horvat, Malcolm R. Starkey, Richard Y. Kim, Kenneth W. Beagley, Julie A. Preston, Peter G. Gibson, Paul S. Foster and Philip M. Hansbro

*J Immunol* 2010; 184:4159-4169; Prepublished online 12 March 2010; doi: 10.4049/jimmunol.0902287
http://www.jimmunol.org/content/184/8/4159

**Supplementary Material**
http://www.jimmunol.org/content/suppl/2010/03/12/jimmunol.0902287.DC1

**References**
This article cites 68 articles, 31 of which you can access for free at:
http://www.jimmunol.org/content/184/8/4159.full#ref-list-1

**Subscription**
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Chlamydial Respiratory Infection during Allergen Sensitization Drives Neutrophilic Allergic Airways Disease

Jay C. Horvat,* Malcolm R. Starkey,* Richard Y. Kim,* Kenneth W. Beagley,*,† Julie A. Preston,* Peter G. Gibson,* Paul S. Foster,* and Philip M. Hansbro*

Neutrophilic asthma is a prevalent, yet recently described phenotype of asthma. It is characterized by neutrophilic rather than eosinophilic airway inflammation and airways hyperresponsiveness (AHR) and may have an infectious origin. Chlamydial respiratory infections are associated with asthma, but how these Th1-inducing bacteria influence Th2-mediated asthma remains unknown. The effects of chlamydial infection on the development of asthma were investigated using a BALB/c mouse model of OVA-induced allergic airways disease (AAD). The effects of current and resolved Chlamydia muridarum infection during OVA sensitization on AAD were assessed and compared with uninfected and nonsensitized controls. Current, but not resolved, infection attenuated hallmark features of AAD: pulmonary eosinophil influx, T cell production of IL-5, mucus-secreting cell hyperplasia, and AHR. Current infection also induced robust OVA-driven neutrophilic inflammation and IFN-γ release from T cells. The phenotype of suppressed but persistent Th2 responses in association with enhanced neutrophilia is reminiscent of neutrophilic asthma. This phenotype was also characterized by increased pulmonary IL-12 and IL-17 expression and activation of APCs, as well as by reduced thymus- and activation-regulated chemokine (MIP-2), the mouse orthologs of human IL-8, inflammatory protein-2 (MIP-2), and reduced Th2 responses in the airways (17). Neutrophilic inflammation in asthma has been associated with viral respiratory infection (18) and correlates with increased activation of innate immune factors, namely, increased IL-8 and TLR-2 and TLR-4 expression in sputum (16). Neutrophil levels are also elevated in the sputum of exacerbating asthmatics with evidence of chlamydial respiratory infection, compared with uninfected individuals (18, 19). Furthermore, increased numbers of neutrophils in the sputum of asthmatics correlate with increased Th1 and reduced Th2 responses in the airways (17). Neutrophilic inflammation in asthma has been associated with viral respiratory infection (18) and correlates with increased activation of innate immune factors, namely, increased IL-8 and TLR-2 and TLR-4 expression in sputum (16). Neutrophil levels are also elevated in the sputum of exacerbating asthmatics with evidence of chlamydial respiratory infection, compared with uninfected individuals (18, 19). Furthermore, chlamydial infection of mice induces a robust pulmonary neutrophil influx that is mediated by the TLR-dependent production of keratinocyte chemokine (KC) and macrophage inflammatory protein-2 (MIP-2), the mouse orthologs of human IL-8 (20, 21). Taken together, these observations suggest that chlamydial infection may be linked to asthma with a neutrophilic phenotype.

Other work has shown that Chlamydia muridarum infection prior to the induction of allergic airways disease (AAD) in mice suppresses pulmonary eosinophil influx, MUC hypersecretion, and allergen-specific Th2 cytokine responses, suggesting that infection may protect against Th2-mediated inflammation during AAD (22, 23).
23). However, we have demonstrated that a *C. muridarum* lung infection in early life results in the generation of both allergen-specific Th2 and Th1 responses. Although the generation of this mixed phenotype results in a suppression of Th2 cytokine production and eosinophils in the airways, the severity of MSC hyperplasia and AHR is increased and inflammation prolonged in later life (9). Clinical studies have also found that respiratory infection may be related to strong IFN-γ and Th1-type responses in moderate to severe asthmatics (24–27). Thus, *Chlamydia*-induced Th1 responses in the asthmatic lung may enhance or modify disease, although Th2-mediated inflammation may be suppressed. Indeed, the presence of both allergen-specific Th1 and Th2 cells in the airways enhance disease in a model of OVA-induced asthma (28).

In this study, we investigated whether *Chlamydia*-induced neutrophilic and Th1 responses during allergen sensitization may subsequently enhance or modify AAD, despite reducing Th2-mediated inflammation. Because immune responses vary during chlamydial lung infection (11, 29), the timing of infection relative to allergic exposure may be important in determining the effects on AAD. Thus, we employed murine models of resolved or current chlamydial lung infection and OVA-induced AAD to examine the effect on neutrophils, Th1 responses, and Th2-mediated AAD. We demonstrated that current chlamydial infection induces the development of AAD with a phenotype reminiscent of neutrophilic asthma.

**Materials and Methods**

**Experimental models**

Six-week-old female BALB/c mice were used throughout. We have previously shown that bacterial recovery (using both real-time PCR and tissue culture) and histopathological status of chlamydial pulmonary infection in adult mice peaks between 10 and 15 d postinoculation. Clearance of infection and the majority of inflammation occur within 21 and 45 d, respectively (9). So that infections were either resolved or at their peak during OVA exposure, mice were infected 45 (D-45) or 7 (D-7) days before OVA sensitization (Fig. 1A). Mice were infected via the intranasal (i.n.) route with 100 inclusion-forming units *C. muridarum* (30 µl, sucrose-phosphate-glutamate buffer). Mice were sensitized to OVA (50 µg [Sigma-Aldrich, Castle Hill, Australia], 1 mg Rehydrogel [Reheis, Berkeley Heights, NJ], and 200 µl 0.9% w/v sterile saline) on day 0 by i.p. injection and were challenged i.n. with OVA 12–15 d later (D-45/OVA and D-7/OVA) (9). One day later, mice were euthanized and AAD was characterized. Controls were; uninfected, allergic (Sal [sham-sensitized with saline]), uninfected and nonallergic (OV A), uninfected and allergic (Sal [sham-sensitized with saline]), or infected and nonallergic (OV A) (9). One day later, mice were euthanized and AAD was characterized. Controls were; uninfected and allergic (OVA); 2) uninfected, nonallergic (Sal); or 3) infected, sham-sensitized (D-45/Sal and D-7/Sal) groups. B. Groups were infected with *C. muridarum* 7 d prior to OVA sensitization (day 0) and were treated with anti-KC and anti–MIP-2 mAbs (αKCMIP2) on 3, 5, 7, and 9 d postinfection (D-4, -2, 0 and 2, αKCMIP2/D-7/OVA). AAD was induced by i.n. OVA challenges on days 12–15 postinfection. The effect of treatment on pulmonary and systemic leukocyte numbers was assessed at the peak of infection (day 3) and before OVA challenge (day 4). Chlamydial numbers in lung tissue were determined at day 5. AAD was assessed 24 h after the final challenge. Controls were; 1) uninfected, isotype-treated, allergic (Iso/OVA); 2) uninfected, Ab-treated, allergic (OVA); 3) infected, Ab-treated, allergic (αKCMIP2/OVA); and 3) infected, isotype-treated, allergic (Iso/D-7) groups. C. Groups were infected with *C. muridarum* 7 d prior to OVA sensitization (day 0). AAD was induced by i.n. OVA challenges on days 12–15 postinfection. Experimental groups were treated with anti–IFN-γ mAb (αIFN-γ) on days 11, 13, and 15 or anti–IL-17 mAb (αIL-17) on days 11 and 13 during OVA challenge (αIFN-γ/D-7/OVA or αIL-17/D-7/OVA, respectively). The effect of treatment on BALF leukocyte numbers was assessed 24 h after the final challenge. Controls were 1) uninfected, isotype-treated, allergic (Iso/OVA); 2) uninfected, Ab-treated, allergic (αKCMIP2/OVA); and 3) infected, isotype-treated, allergic (Iso/D-7) groups.

**Histopathological findings and airway inflammation**

Lungs were perfused (0.9% saline) and fixed by inflation with formalin (1.5 ml, 10% buffered formalin: Sigma-Aldrich). The trachea was tied off, and staining using toluidine blue and eosin (4–6 µm) and stained using hematoxylin and eosin (H&E) (9). All samples were coded and counts performed in a blinded fashion.

**T cell cytokines**

Cytokine release from lung draining mediastinal lymph node (MLN) cells was determined by ELISA (9). Cells (5 × 10^6) were cultured in RPMI (1 ml, 10% FBS, 20 mM HEPES, 10 µg/ml penicillin/streptomycin, 2 mM L-glutamine, and 50 µM 2-ME) and restimulated with OVA (200 µg/ml) for 6 d. Concentrations of IFN-γ, IL-5, and IL-13 were determined in supernatants using mouse IFN-γ and IL-5 (BD Biosciences, North Ryde, Australia) and IL-13 (R&D Systems, Gymea, Australia) Ab combinations according to the manufacturers’ instructions (9).
Laboratories, Smithfield, Australia), and the trachea was cannulated and connected to an inline aerosol and ventilator, which were attached to a preamplifier and computer (Buxco Electronics, Sharon, CT). Airways resistance and dynamic compliance were determined in response to increasing doses of methacholine (Sigma-Aldrich).

**Suppression of neutrophil influx**

To assess the influence of neutrophil influx into the lungs during chlamydial infection on infection-associated changes during AAD, mice were injected i.p. with a combination of anti-KC and anti–MIP-2 (18 μg and 4 μg, respectively [αKCMIP2, R&D Systems], in 200 μl PBS) or corresponding isotype control Abs (18 μg and 4 μg, Rat IgG2a and IgG2b, respectively [Iso; R&D Systems]). Treatment occurred 3, 5, 7, and 9 d postinfection. On day 7, mice were sensitized and subsequently challenged with OVA (Fig. 1B). One day later, mice were euthanized and AAD was characterized. Controls were uninfected and treated with αKCMIP2 or isotype control Abs.

**Pulmonary cytokine expression**

Pulmonary cytokine expression was evaluated by real-time PCR (30). Total RNA was extracted from whole-lung tissue, using TRIzol according to the manufacturer’s instructions (Invitrogen, Mount Waverley, Australia). Reverse transcription of RNA (1000 ng) was performed using Superscript III and random hexamer primers (Invitrogen). Relative abundance of genes was determined by comparison with the reference gene hypoxanthine-guanine phosphoribosyltransferase, using a Prism7000 Sequence Detection System (Applied Biosystems, Scoresby, Australia). Primers used were IL-12, Fwd 5′-ACC AGC TTC TTC ATG GAC ATC ATC-3′, Rev 5′-TCT CTCA CGA GGA ACG CAC CTT-3′; IL-17, Fwd 5′-CAA ACA TGA GTG GAT GGC GGT GGA TTT GAA-3′, Rev 5′-ACT GAG CTT CCC AGA TCA-3′; and hypoxanthine-guanine phosphoribosyltransferase, using a Primer7000 Sequence Detection System (Applied Biosystems, Scoresby, Australia). Primers used were IL-12, Fwd 5′-ACC AGC TTC TTC ATG GAC ATC ATC-3′, Rev 5′-TCT CTCA CGA GGA ACG CAC CTT-3′; IL-17, Fwd 5′-CAA ACA TGA GTG GAT GGC GGT GGA TTT GAA-3′, Rev 5′-ACT GAG CTT CCC AGA TCA-3′; and hypoxanthine-guanine phosphoribosyltransferase, Fwd 5′-AGG CCA GAC TTT GGT GGA TTT GAA-3′, Rev 5′-CAA CTG CTC CTC ATC TTA GGC TTT-3′.

**Lung tissue cells**

Single-cell suspensions of collagenase-d-digested lungs (1 × 10⁶ cells) were stained for surface markers (31). Cells were characterized as follows: neutrophils, CD11c−CD11b−Gr1−, low-moderate forward scatter and moderate-high side scatter; plasmacytoid dendritic cells (pDC), CD11c+CD11b+Gr1+, moderate forward scatter and low-moderate side scatter; and myeloid dendritic cells (mDC), CD11c+CD11b+Gr1+, moderate forward scatter and low-moderate side scatter. Maturation and activation of dendritic cells (DCs) were assessed by determination of MHC II expression. The functional capacity of pulmonary APCs (CD11c+) was also assessed by analyzing expression of the costimulatory markers CD80 and CD86.

**Depletion of IFN-γ and IL-17**

Groups were infected with *C. muridarum* 7 d prior to OVA sensitization. AAD was induced by i.n. OVA challenges on days 12–15 postsensitization. Experimental groups were infected 7 (D-7/OVA) or 45 (D-45/OVA) d prior to OVA sensitization and challenge, as described in Fig. 1A. Total leukocyte (A), neutrophil (B), and eosinophil (C) numbers were determined in BALF. Results are presented as mean ± SEM from *n* ≥ 4, in duplicate, with allergic groups represented by black bars and nonallergic controls by white bars. Significant differences between groups are shown as *p* < 0.05, ***p* < 0.01, and ****p* < 0.001.

**Statistics**

Results are presented as mean ± SEM from between 4 and 8 mice, in duplicate or triplicate experiments. Statistical significance of whole data sets was initially confirmed using one-way ANOVA. The Wilcoxon rank-sum test was used for nonparametric tests (Mann-Whitney *U* test for two independent samples). Comparison of airways resistance and dynamic compliance between groups was performed using one-way repeated measures ANOVA, and significance was assessed for the entire dose-response curve.

**Results**

**Development of AAD**

Compared with uninfected, nonallergic (Sal) groups, allergic groups without infection (OVA; Fig. 1) displayed hallmark features of Th2-driven AAD characterized by eosinophil influx into the airways (Fig. 2) and tissue (Fig. 3), airways MSC hyperplasia (Fig. 3), OVA-specific Th2 cytokine responses from MLN T cells (Fig. 4), and AHR (Fig. 5).

**Infection and AAD**

To investigate the effect of current or resolved infection on the development of AAD, groups were infected 7 or 45 d before sensitization (Fig. 1A). There were no significant differences in bacterial recovery from the lungs of infected allergic groups, compared with infected, nonallergic controls (data not shown).

**Current infection during sensitization alters cellular responses during AAD**

The effects of infection on cellular responses during AAD were assessed. Current (D-7/OVA), but not resolved (D-45/OVA), infection during sensitization had substantial effects on immune cell influx into the lungs during OVA-induced AAD.

Although current infection had minimal effects on the influx of total leukocytes (Fig. 2A), macrophages, or lymphocytes (not shown) into the BALF during AAD, the numbers of neutrophils were significantly increased, whereas eosinophil influx was attenuated.
compared with that in uninfected, allergic (OVA) controls (Fig. 2B, 2C). By contrast, resolved infection suppresses eosinophil numbers only in the BALF. Current, but not resolved, infection also attenuated the numbers of tissue eosinophils and MSCs in the airways (Fig. 3A, 3B). Notably, the increased recruitment of neutrophils to the airways correlated with OVA-induced mobilization of neutrophils into the blood (Fig. 3C).

Current infection during AAD (D-7/OVA) also significantly increased neutrophils in BALF and blood, compared with infection in the absence of AAD (D-7/Sal; Figs. 2B, 2C). This indicates that the influx of neutrophils during AAD occurs in response to OVA sensitization and challenge, suggesting that infection primes for the neutrophil influx during AAD.

**Current infection during sensitization drives allergen-specific Th1 T cell cytokine responses during AAD**

The mobilization of neutrophils into the blood during allergen challenge suggested that OVA-specific Th1 cells had been generated during sensitization. To assess the effect of infection on OVA-specific T cell cytokine responses, MLN T cells were cultured with OVA. T cells from uninfected mice with AAD (OVA) produced strong OVA-specific Th2 responses characterized by substantial increases in the production of IL-5 and IL-13, compared with T cells from uninfected, nonallergic controls (Sal; Fig. 4B, 4C). By contrast, T cells from mice that had a current infection during OVA sensitization released substantially increased levels of OVA-specific IFN-γ, suppressed IL-5 (Fig. 4A, 4B), but unaltered IL-13 release (p = 0.17; Fig. 4C), compared with T cells from uninfected, allergic (OVA) controls. A resolved infection (D-45/OVA) had no effect on IFN-γ or IL-5 production but decreased IL-13 levels.

**Current infection during sensitization suppresses AHR to methacholine**

The effects of infection on AHR during AAD were assessed. The induction of AAD without infection (OVA) resulted in the development of AHR, characterized by increased airway resistance and decreased compliance, compared with findings in uninfected, nonallergic controls (Sal; Fig. 5). Current, but not resolved, infection suppressed AHR.

Current infection during sensitization (D-7/OVA) resulted in reduced AHR with decreased resistance and increased compliance.
compared with findings in uninfected, allergic (OVA) controls (Fig. 5). By contrast, a resolved infection (D-45/OVA) had no effect. Notably, infected, nonallergic groups, regardless of the timing of infection (D-7/Sal and D-45/Sal), had increased AHR, compared with uninfected, nonallergic (Sal) controls, indicating that infection alone altered baseline lung function.

Suppression of neutrophil influx during infection

Chlamydial lung infections induce potent neutrophil influx into the lungs (20, 32); therefore, the effects of these cellular responses to infection on AAD were investigated. First, the effectiveness of suppressing neutrophil influx during infection by treatment with αKCMIP2 to reduce the levels of the chemotactic chemokines KC and MIP-2 was assessed. The effects of Ab treatment on leukocyte influx during infection in the absence of AAD (i.e., without sensitization or challenge with OVA) were determined. Pulmonary neutrophil, but not lymphocyte, influx was reduced in infected, Ab-treated (αKCMIP2/D-7) groups, compared with untreated (Iso/D-7) controls, 10 d post-infection (Supplemental Fig. 1A). This finding is equivalent to day 3 of the experimental model (Fig. 1B) and is the time of peak infection. Neutrophil numbers were reduced by 52% in the BALF. However, treatment had no effect on the percentage of neutrophils in the blood (Supplemental Fig. 1B). Treatment did not affect infection, with no change in the number of chlamydia recovered from the lungs (Supplemental Fig. 1C).

Suppression of neutrophil influx during infection alters cellular responses in Chlamydia-driven neutrophilic AAD

Next, the influence of neutrophil influx into the lungs during infection on AAD was assessed. This was achieved by suppressing neutrophil influx during infection and analyzing the effects on the subsequent development of OVA-induced AAD (Fig. 1B). Treatment during infection reduced neutrophil influx into the lung and blood in AAD (αKCMIP2/D-7/OVA), compared with isotype-treated (Iso/D-7/OVA) controls. Neutrophil numbers were reduced by 48% in BALF, 65% in lung tissue, and 63% in blood (Fig. 6A–C).

We investigated whether the reduction in neutrophils in AAD resulted from removing the effects of neutrophils during infection or from a direct influence of Ab treatment on neutrophil influx during the challenge phase of AAD. To find out, neutrophil numbers in lungs and blood were assessed on day 12 (D12; Fig. 1B) of the experimental protocol, when groups had been infected and sensitized with OVA but prior to OVA challenge. Ab treatment did not alter the numbers of neutrophils in lungs or blood, compared with findings in isotype-treated controls prior to OVA challenge (not shown). Therefore, the influence of treatment on neutrophil numbers during infection-induced AAD resulted from suppression of the effects of neutrophils during infection and not from the prolonged effects of Abs on neutrophil influx during the challenge phase of the model.

Taken together, these results show that suppression of neutrophil influx during infection leads to suppression of neutrophil numbers.

FIGURE 5. AHR postinfection and AAD. AHR was determined in experimental groups infected (A) 7 (D-7/OVA) or (B) 45 (D-45/OVA) d before OVA sensitization and challenge, as described in Fig. 1A. AHR is expressed in terms of airways resistance (upper panels) and dynamic compliance (lower panels) in response to increasing doses of methacholine. Comparison of statistical differences across whole curves is shown in the tables. Results are presented as mean ± SEM from $n = 4$, in duplicate. Significant differences between groups are shown as *$p < 0.05$, **$p < 0.01$, and ***$p < 0.001$. **
in the airways and blood during AAD. This occurs despite neutrophil numbers being similar between infected groups prior to OVA challenge.

The suppression of neutrophil influx during infection removed the suppressive effects of infection on MSC numbers during AAD (Fig. 6D). However, treatment did not alter the infection-induced reduction of pulmonary eosinophil numbers during AAD (Supplemental Fig. 2A, 2B).

Reduction of pulmonary neutrophil influx during infection alters T cell responses in Chlamydia-driven neutrophilic AAD

The suppression of neutrophil influx during infection reversed the effects of infection on OVA-specific cytokine release from MLNs during AAD. Ab treatment of infected and allergic (αKCMIP2/D-7/OVA) groups substantially reduced OVA-specific IFN-γ release, compared with that in infected, isotype-treated (Iso/D-7/OVA) controls (Fig. 6E). Treatment also increased IL-5 release by >2-fold, compared with controls, however, these levels were still significantly lower than those in Ab- (αKCMIP2/OVA) or isotype-treated, uninfected, allergic (Iso/OVA) groups (Supplemental Fig. 2C). Treatment did not affect IL-13 levels in infected, allergic (αKCMIP2/D-7/OVA) groups (Supplemental Fig. 2D).

Reduction of pulmonary neutrophil influx during infection alters AHR in Chlamydia-driven neutrophilic AAD

Reduced neutrophil influx into the lungs during infection completely reversed the suppressive effect of infection on AHR during AAD. Treatment (αKCMIP2/D-7/OVA) significantly increased resistance ($p < 0.01$) and decreased compliance ($p = 0.06$), compared with findings in isotype-treated (Iso/D-7/OVA) controls (Fig. 7). No differences were found between treated, infected, and allergic (αKCMIP2/D-7/OVA) groups and Ab- or isotype-treated, uninfected, allergic (αKCMIP2/OVA and Iso/OVA) controls.

Current infection during sensitization affects the expression of immune mediators in the lung during AAD, which are partially reversed by reduction of pulmonary neutrophil influx during infection

The mechanisms of how infection modulates the phenotype and inflammatory profile of OVA-induced AAD were further investigated.
Chlamydial infections induce or alter the release of a variety of immune factors, including IL-12 and IL-17 and TARC, that may influence AAD. Current infection resulted in significant increases in IL-12 and IL-17 and decreased TARC expression in the lungs during AAD (Iso/D-7/OVA), compared with findings in uninfected, allergic (Iso/OVA) controls (Fig. 8A–C). Significantly, suppression of neutrophil influx into the lungs during infection partially reversed these changes. Ab-treated (αKCMIP2/D-7/OVA) groups had significantly decreased IL-12 and IL-17 and increased TARC expression in the lungs, compared with isotype-treated (Iso/D-7/OVA) controls (Fig. 8A–C).

**Current infection during sensitization increases APC activation in the lung during AAD, which is altered by reduction of pulmonary neutrophil influx during infection**

Infections may also alter the phenotype and function of APCs, which may influence how infection modulates AAD. Current infection increased the numbers of MHC II+ mDCs and costimulatory factors on APCs in lung tissue in AAD. Current infection (Iso/D-7/OVA) increased the number of viable cells that were MHC II+ mDCs and pDCs and APCs (CD11c+ cells) expressing CD80 and CD86 in the lungs during AAD, compared with findings in uninfected, allergic (Iso/OVA) controls (Fig. 8D–G).

Ab treatment during infection (αKCMIP2/D-7/OVA) increased the number of MHC II+ pDCs in the lungs during AAD over that seen in isotype-treated, infected (Iso/D-7/OVA) controls (Fig. 8D, 8E). This occurred despite treatment having no effect on the level of infection and therefore on antigenic load in the lungs. Treatment reversed the effect of infection on the number of APCs expressing CD80 during AAD (Fig. 8F) but had no effect on CD86 expression (Fig. 8G). Ab treatment in the absence of infection (αKCMIP2/OVA) did not substantially influence DCS or APCs, compared with findings in uninfected isotype-treated (Iso/D-7/OVA) controls (Fig. 8D–G).

**Increased levels of IFN-γ and IL-17 during OVA challenge do not play a critical role in infection-induced neutrophilic AAD**

We have shown that infection-induced changes in AAD are associated with increased IFN-γ and IL-17 responses following OVA challenge. To investigate the role of these cytokines in infection-induced neutrophilic AAD, αIFN-γ or αIL-17 mAbs were administered during OVA challenge (Fig. 1C). Infected, allergic groups that were treated with αIFN-γ (αIFN-γ/D-7/OVA) had increased numbers of neutrophils in BALF, compared with both uninfected, Ab- and isotype-treated (αIFN-γ/OVA and OVA) groups (Fig. 9). Significantly, treatment of infected, allergic groups with αIFN-γ (αIFN-γ/D-7/OVA), compared with infected, isotype-treated (D-7/OVA) controls, did not affect neutrophil numbers (Fig. 9). Similar results were observed with αIL-17 treatment (not shown). Therefore, although infection-induced changes in AAD are associated with augmented Th1/Th17 immunity, increased IFN-γ and IL-17 responses during OVA challenge do not play a critical role in driving neutrophilic inflammation in infection-induced neutrophilic AAD.

**Discussion**

In this paper, we show that chlamydial infection promotes neutrophilic inflammation and OVA-specific Th1 responses and suppresses Th2-mediated eosinophilic inflammation, resulting in a phenotype reminiscent of that of neutrophilic asthma. This phenotype was largely reversed by suppression of neutrophil influx into the lung during infection.

These studies employed the natural mouse pathogen C. muridarum, which was originally isolated from a mouse with respiratory infection (33, 34). The time course, as well as the immunological and histopathological progression, of C. muridarum infection of mice closely resembles that observed with Chlamydia pneumoniae infection in humans (8, 9). Therefore, C. muridarum is the organism of choice for investigating natural host–bacteria–allergen interactions in mice.
The current and previous studies have reported that a resolved chlamydial infection during AAD either has no effect or suppresses key features of asthma in AAD (22, 23). Although the effects of resolved infection investigated in previous studies resulted in a suppression of Th2, and an increase in Th1 responses, the authors did not investigate the effects of an ongoing infection or demonstrate an increase in neutrophilic inflammation or the effects of infection on AHR. We have extended these studies to show that, although an active infection suppressed Th2 responses, infection should not be considered protective; rather, it changes...
the phenotype of AAD to one underpinned by neutrophilic inflammation that is associated with allergen-specific Th1 (IFN-γ) responses. Neutrophilic inflammation plays an important role during acute exacerbations of asthma, and respiratory pathogens may be implicated in these events (18, 19, 35–37). More than one-third of asthmatics presenting with acute severe asthma exacerbations had elevated levels of *Chlamydia pneumoniae*-specific IgG or IgA, indicating an acute or reactivated infection (19). These subjects exhibited more intense neutrophilic inflammation, compared with acute exacerbators without infection. Our results show that AHR in groups with current infection in AAD was reduced to the same level as that induced by infection alone, but lung function was impaired in both groups, compared with uninfected, nonallergic controls. This observation suggests that infection suppresses AHR that is associated with AAD; however, infection alone impairs lung function. Clinical studies show that increased *Chlamydia pneumoniae* Ab levels are associated with persistent airflow limitation in adult-onset, nonatopic asthmatics (38). Therefore, infection may result in abnormal lung function in the absence of Th2-mediated allergic responses in humans. *Chlamydia*-driven neutrophilic asthma may also be a more protracted or chronic disease (39). Infection may result in a perpetuating feedback loop in which the neutrophilic phenotype is reinforced and prolonged, resulting in the induction of chronic disease. *Chlamydia* is able to infect and grow in neutrophils (21, 40), and infected neutrophils have delayed apoptosis and secrete greater amounts of IL-8 (40). This characteristic may promote further neutrophil influx, resulting in the persistence of neutrophils within the airways during infection (40) and neutrophil-dominated asthma.

The switch toward a neutrophil-dominated phenotype correlated with increased pulmonary expression of IL-12 and IL-17, which may contribute to the suppression of Th2 responses during AAD (41). IL-12 is associated with Th1 polarization (42), whereas IL-17 is important in driving neutrophilic inflammation (43, 44). Recently, increased levels of IL-17 were detected in the airways of asthmatic patients and correlated with elevated neutrophil numbers in sputum and more severe disease (45). Taken together, our observations may help explain the clinical link between *Chlamydia* and asthma. Infection may promote neutrophilic inflammation that is associated with Th1 and IL-17 responses, rather than Th2-dominated, eosinophilic responses, while maintaining some of the clinical features of asthma, such as impaired lung function. Th1 and Th17 responses have been previously shown to be associated with neutrophilic inflammation in mouse models of AAD; however, these studies used adoptive transfer of in vitro polarized Th1 and Th17 cells to demonstrate the link (46, 47). In this study, we show that chlamydial infection may drive Th1- and Th17-biased immune responses against allergens during AAD.

Neutrophilic asthma is difficult to treat, as patients are resistant to corticosteroids, which are the mainstay of asthma therapy (48, 49). Steroid treatment also decreases neutrophil apoptosis and increases neutrophil numbers in serum and tissue (50–52). Therefore, treatment may increase neutrophil numbers and perpetuate neutrophilia in the lung. Steroid treatment also promotes chlamydial infection in vitro and reactivates persistent lung infection in vivo (53, 54), and asthmatic patients on high, as opposed to low, doses of inhaled steroids are more likely to have evidence of *Chlamydia pneumoniae* infection (55). Most importantly, asthmatics with evidence of infection are more resistant to steroid treatment than are asthmatics without infection (56). These observations suggest that treatment may result in increased susceptibility to acute infection or reactivation of persistent chlamydial lung infection and that infection induces a phenotype of asthma that is more resistant to treatment. Therefore, alternative therapies may need to be considered when treating asthmatics with evidence of *Chlamydia*-driven neutrophilic inflammation.

Because an association exists between increased activation of innate immune factors and neutrophilic asthma (16), we hypothesized that the influx of neutrophils into the lungs may drive the development of neutrophilic AAD. To investigate this, the inflammatory chemokines KC and MIP-2 were inhibited during infection. Treatment resulted in ~50% reduction in neutrophils in the lungs during infection. A lack of complete inhibition may be explained by the existence of non–CXCR2-dependent redundancies in chemotactic signaling, including C5a and MCP-1, which signals through CCR2 (57, 58). Systemic leukocyte numbers were not altered, indicating that only cellular influx into the lung, and not mobilization from the bone marrow, was affected. However, treatment during infection did suppress pulmonary and circulating neutrophil responses during subsequent AAD. This observation suggests that neutrophil accumulation during infection is necessary to prime for both local and systemic neutrophil responses during AAD. Importantly, treatment also reversed infection-driven alterations in OVA-specific IFN-γ levels, MSC numbers, and AHR during AAD. Treatment ceased 10 d before OVA challenge and had no significant effect on AAD in uninfected, allergic controls, demonstrating that Ab treatment had no direct or prolonged influence on AAD. Furthermore, neutrophil numbers were similar between Ab-treated and isotype control groups prior to the induction of AAD by OVA challenge. This finding shows that changes in the phenotype of AAD were related to the effects of infection. This also confirms that the suppression of neutrophil numbers by Ab treatment during infection results from a diminished ability to recruit neutrophils upon exposure to an allergen. Whether the effects of treatment result from lower numbers of neutrophils infiltrating the lungs during sensitization or from reduced de novo recruitment of neutrophils after allergen challenge remains unknown. Taken together, these data demonstrate that neutrophil influx into the lungs during infection plays an important role in driving the hallmark features of infection associated neutrophilic AAD.

The effect of treatment on pulmonary levels of IL-12, IL-17, and TARC and changes in APC activation during AAD demonstrates that the influx of neutrophils during infection is necessary to induce
a range of immune changes in *Chlamydia*-induced neutrophilic AAD. Treatment reduced IL-12 and IL-17 levels, which correlated with decreased Ag-specific Th1 responses and neutrophilic inflammation. Increased TARC expression posttreatment may have enhanced the chemotraction of Th2 cells (59, 60), which may explain the reinstatement of features of Th2-driven AAD (i.e., MSC hyperplasia and AHR). Increased MSC hyperplasia and AHR may also have resulted from increased pDC numbers, which promote T cell stimulation and inflammation during AAD. Finally, the correlation of decreased CD80 costimulation with reduced Th1 cytokine responses supports the concept that CD80 costimulation is associated with the activation and polarization of Th1 responses (61–63).

The effect of treatment on IFN-γ responses and DC number and phenotype during AAD suggests that the influx of neutrophils into the lungs during infection substantially alters the manner in which T cells are activated during AAD. Neutrophil activation may modify DC maturation and activation (64–66) and enhance the release of IL-12 and TNF-α from DCs (65), suggesting that neutrophil responses play a crucial role in influencing DCs to induce Th1 responses upon contact with T cells. Furthermore, neutrophils can present Ag to T cells and induce T cell proliferation and cytokine release (67, 68). Thus, the accumulation of neutrophils in the lungs during infection may play a key regulatory role during AAD by modulating local DC number and function, as well as DC-mediated T cell responses, or by directly interacting with T cells. Importantly, stimulation of DCs via CXCXR2 does not affect DC activation or migration (69), suggesting that αMβ2integrin has no direct influence on DC number or phenotype in the lungs.

The depletion of IFN-γ or IL-17 during OVA challenge did not affect neutrophilic inflammation in *Chlamydia*-induced neutrophilic AAD. This finding demonstrates that neither IFN-γ nor IL-17 plays a critical mechanistic role during the challenge phase of *Chlamydia*-induced neutrophilic AAD. Depletion during sensitization and infection phases of the experimental models is not appropriate, as both IFN-γ and IL-17 are induced by and are required for the clearance of chlamydial respiratory infection (10, 11, 70). Thus, the absence of these factors during infection would dramatically change the profile and magnitude of infection and subsequently the responses to OVA. However, collectively, these results suggest that infection-induced neutrophilic responses alter allergic sensitization and drive the development of neutrophilic AAD that is associated with Th1/Th17 rather than Th2 responses.

Further experimental and clinical studies of the association between chlamydial infection-induced inflammatory responses and neutrophilic asthma may lead to novel treatments for individuals with this subtype of disease.

In summary, chlamydial infection may contribute to AAD by inducing neutrophil influx, which promotes a phenotype resembling that of neutrophilic asthma. These responses are associated with increased APC activation and expression of IL-12 and IL-17, suggesting that *Chlamydia*-induced neutrophilic AAD is associated with (but not directly regulated by) augmented Th1 and Th17 immune responses. Significantly, the influx of neutrophils in response to infection may play a novel role in driving neutrophilic AAD and associated Th1/Th17 responses.

Acknowledgments
We thank Prof. Rakesh Kumar (Department of Pathology, University of New South Wales, Sydney, Australia) for assistance in the analysis of changes in lung histology.

Disclosures
The authors have no financial conflicts of interest.
Online Supplement Figure 1. Suppression of neutrophil influx into the lungs during infection. Experimental groups were infected and treated with anti-KC and anti-MIP-2 mAbs (αKCMIP2) during infection (αKCMIP2/D-7) and were sacrificed 10 days after infection. This is equivalent to day 3 of the experimental model, described in Figure 1B, and is the time of peak infection. Airways (A) neutrophil numbers were determined in BALF, while percentages of leukocytes that were (B) neutrophils were assessed in blood. Chlamydial numbers, expressed as ifu/lung (C) were determined in lung tissue by real-time PCR. Results are presented as mean±SEM. Significant differences between groups are shown as *p<0.05.
Online Supplement Figure 2. Effect of the suppression of neutrophil influx during infection on hallmark features of infection-induced neutrophilic AAD.

Experimental groups were infected 7 days before Ova sensitization and treated with anti-KC and anti-MIP-2 mAbs (αKCMIP2) during infection. AAD was induced and assessed (αKCMIP2/D-7/Ova) as described in Figure 1B. Eosinophils were enumerated in (A) BALF. Lung sections were also examined by histology to determine (B) airway tissue eosinophil numbers within 100μm of basement membrane (BM). MLN production of Ova-specific (C) IL-5 and (D) IL-13 was determined in culture supernatants using ELISA. Results are presented as mean±SEM from n≥4, in duplicate with αKCMIP2 treatment represented by white bars and isotype-treatment represented by black bars. Significant differences between groups are shown as *p<0.05, **p<0.01 and ***p<0.001.